EGFR and adenocarcinoma: The discovery of mutations and rearrangements including epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK), and ROS proto‐oncogene 1 (ROS1) rearrangements has led to the development of specific targeted agents and dramatically altered the therapeutic landscape, particularly regarding adenocarcinomas.3